NDAINJECTIONINJECTABLE
Approved
Jan 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
LIPOSYN III 30% (soybean oil) by Pfizer is patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. First approved in 1998.
Drug data last refreshed 3d ago
Mechanism of Action
patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Soybean Oil Trial of cArdiovascular Risk
Started Mar 2015
60 enrolled
Cardiovascular DiseaseDiabetesMetabolic Syndrome
Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN
Started Nov 2008
100 enrolled
Parenteral Nutrition
Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers
Started Jun 2008
12 enrolled
Diseases, MetabolicInsulin Sensitivity
Worked on LIPOSYN III 30% at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.